{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,24]],"date-time":"2026-09-24T08:24:55Z","timestamp":1790238295690,"version":"4.1.0"},"reference-count":35,"publisher":"Springer Science and Business Media LLC","issue":"9","license":[{"start":{"date-parts":[[2015,7,19]],"date-time":"2015-07-19T00:00:00Z","timestamp":1437264000000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Childs Nerv Syst"],"published-print":{"date-parts":[[2015,9]]},"DOI":"10.1007\/s00381-015-2812-5","type":"journal-article","created":{"date-parts":[[2015,7,18]],"date-time":"2015-07-18T09:07:01Z","timestamp":1437210421000},"page":"1433-1445","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":15,"title":["A phase I trial and PK study of cediranib (AZD2171), an orally bioavailable pan-VEGFR inhibitor, in children with recurrent or refractory primary CNS tumors"],"prefix":"10.1007","volume":"31","author":[{"given":"Mark W.","family":"Kieran","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Susan","family":"Chi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stewart","family":"Goldman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Arzu","family":"Onar-Thomas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tina Young","family":"Poussaint","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sridhar","family":"Vajapeyam","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Frederic","family":"Fahey","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shengjie","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David C.","family":"Turner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Clinton F.","family":"Stewart","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marsha","family":"Moses","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roger J.","family":"Packer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Regina","family":"Jakacki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anu","family":"Banerjee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"James M.","family":"Boyett","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maryam","family":"Fouladi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Larry","family":"Kun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2015,7,19]]},"reference":[{"key":"2812_CR1","doi-asserted-by":"crossref","first-page":"775","DOI":"10.2217\/fon.12.73","volume":"8","author":"M Sahade","year":"2012","unstructured":"Sahade M, Caparelli F, Hoff PM (2012) Cediranib: a VEGF receptor tyrosine kinase inhibitor. Future Oncol 8:775\u2013781","journal-title":"Future Oncol"},{"key":"2812_CR2","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1007\/s11060-005-4570-9","volume":"76","author":"C Haberler","year":"2006","unstructured":"Haberler C, Gelpi E, Marosi C, et al. (2006) Immunohistochemical analysis of platelet-derived growth factor receptor-alpha, -beta, c-kit, c-abl, and arg proteins in glioblastoma: possible implications for patient selection for imatinib mesylate therapy. J Neuro-Oncol 76:105\u2013109","journal-title":"J Neuro-Oncol"},{"key":"2812_CR3","doi-asserted-by":"crossref","first-page":"4389","DOI":"10.1158\/0008-5472.CAN-04-4409","volume":"65","author":"SR Wedge","year":"2005","unstructured":"Wedge SR, Kendrew J, Hennequin LF, et al. (2005) AZD2171: a highly potent, orally bioavailable, vascular endothelial growth factor receptor-2 tyrosine kinase inhibitor for the treatment of cancer. Cancer Res 65:4389\u20134400","journal-title":"Cancer Res"},{"key":"2812_CR4","doi-asserted-by":"crossref","first-page":"8662","DOI":"10.1158\/0008-5472.CAN-10-1435","volume":"70","author":"JJ Yin","year":"2010","unstructured":"Yin JJ, Zhang L, Munasinghe J, Linnoila RI, Kelly K (2010) Cediranib\/AZD2171 inhibits bone and brain metastasis in a preclinical model of advanced prostate cancer. Cancer Res 70:8662\u20138673","journal-title":"Cancer Res"},{"key":"2812_CR5","doi-asserted-by":"crossref","first-page":"2542","DOI":"10.1200\/JCO.2008.19.9356","volume":"27","author":"WS Kamoun","year":"2009","unstructured":"Kamoun WS, Ley CD, Farrar CT, et al. (2009) Edema control by cediranib, a vascular endothelial growth factor receptor-targeted kinase inhibitor, prolongs survival despite persistent brain tumor growth in mice. J Clin Oncol 27:2542\u20132552","journal-title":"J Clin Oncol"},{"key":"2812_CR6","volume-title":"WHO classification of tumours of the central nervous system","year":"2007","unstructured":"Louis DN, Ohgaki H, Wiestler OD, Cavenee WK (eds) (2007) WHO classification of tumours of the central nervous system. International Agency for Research on Cancer, Lyon"},{"key":"2812_CR7","doi-asserted-by":"crossref","first-page":"581","DOI":"10.1002\/pbc.21232","volume":"50","author":"JM Maris","year":"2008","unstructured":"Maris JM, Courtright J, Houghton PJ, et al. (2008) Initial testing of the VEGFR inhibitor AZD2171 by the pediatric preclinical testing program. Pediatr Blood Cancer 50:581\u2013587","journal-title":"Pediatr Blood Cancer"},{"key":"2812_CR8","doi-asserted-by":"crossref","first-page":"1021","DOI":"10.1007\/s00280-013-2097-x","volume":"71","author":"J Kendrew","year":"2013","unstructured":"Kendrew J, Odedra R, Logie A, et al. (2013) Anti-tumour and anti-vascular effects of cediranib (AZD2171) alone and in combination with other anti-tumour therapies. Cancer Chemother Pharmacol 71:1021\u20131032","journal-title":"Cancer Chemother Pharmacol"},{"key":"2812_CR9","doi-asserted-by":"crossref","first-page":"566","DOI":"10.1002\/pbc.23159","volume":"58","author":"CL Morton","year":"2011","unstructured":"Morton CL, Maris JM, Keir ST, et al. (2011) Combination testing of cediranib (AZD2171) against childhood cancer models by the pediatric preclinical testing program. Pediatr Blood Cancer 58:566\u2013571","journal-title":"Pediatr Blood Cancer"},{"key":"2812_CR10","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1016\/j.ccr.2006.11.021","volume":"11","author":"TT Batchelor","year":"2007","unstructured":"Batchelor TT, Sorensen AG, di Tomaso E, et al. (2007) AZD2171, a pan-VEGF receptor tyrosine kinase inhibitor, normalizes tumor vasculature and alleviates edema in glioblastoma patients. Cancer Cell 11:83\u201395","journal-title":"Cancer Cell"},{"key":"2812_CR11","doi-asserted-by":"crossref","first-page":"2817","DOI":"10.1200\/JCO.2009.26.3988","volume":"28","author":"TT Batchelor","year":"2010","unstructured":"Batchelor TT, Duda DG, di Tomaso E, et al. (2010) Phase II study of cediranib, an oral pan-vascular endothelial growth factor receptor tyrosine kinase inhibitor, in patients with recurrent glioblastoma. J Clin Oncol 28:2817\u20132823","journal-title":"J Clin Oncol"},{"key":"2812_CR12","doi-asserted-by":"crossref","unstructured":"Sridhar SS, Mackenzie MJ, Hotte SJ, Mukherjee SD, Tannock IF, Murray N, Kollmannsberger C, Haider MA, Chen EX, Halford R, Wang L, Ivy SP, Moore MJ. A phase II study of cediranib (AZD 2171) in treatment naive patients with progressive unresectable recurrent or metastatic renal cell carcinoma. A trial of the PMH phase 2 consortium. Invest New Drugs. 2013 31(4):1008-1015. doi: 10.1007\/s10637-013-9931-1 PMID:2335484913.","DOI":"10.1007\/s10637-013-9931-1"},{"key":"2812_CR13","doi-asserted-by":"crossref","first-page":"5174","DOI":"10.1200\/JCO.2010.30.9674","volume":"28","author":"E Fox","year":"2010","unstructured":"Fox E, Aplenc R, Bagatell R, et al. (2010) A phase 1 trial and pharmacokinetic study of cediranib, an orally bioavailable pan-vascular endothelial growth factor receptor inhibitor, in children and adolescents with refractory solid tumors. J Clin Oncol 28:5174\u20135181","journal-title":"J Clin Oncol"},{"key":"2812_CR14","doi-asserted-by":"crossref","first-page":"445","DOI":"10.1007\/s10637-007-9050-y","volume":"25","author":"CJ Ryan","year":"2007","unstructured":"Ryan CJ, Stadler WM, Roth B, et al. (2007) Phase I dose escalation and pharmacokinetic study of AZD2171, an inhibitor of the vascular endothelial growth factor receptor tyrosine kinase, in patients with hormone refractory prostate cancer (HRPC). Investig New Drugs 25:445\u2013451","journal-title":"Investig New Drugs"},{"key":"2812_CR15","doi-asserted-by":"crossref","first-page":"3045","DOI":"10.1200\/JCO.2006.07.2066","volume":"25","author":"J Drevs","year":"2007","unstructured":"Drevs J, Siegert P, Medinger M, et al. (2007) Phase I clinical study of AZD2171, an oral vascular endothelial growth factor signaling inhibitor, in patients with advanced solid tumors. J Clin Oncol 25:3045\u20133054","journal-title":"J Clin Oncol"},{"key":"2812_CR16","doi-asserted-by":"crossref","first-page":"477","DOI":"10.2215\/CJN.08111109","volume":"5","author":"ES Robinson","year":"2010","unstructured":"Robinson ES, Matulonis UA, Ivy P, et al. (2010) Rapid development of hypertension and proteinuria with cediranib, an oral vascular endothelial growth factor receptor inhibitor. Clin J Am Soc Nephrol 5:477\u2013483","journal-title":"Clin J Am Soc Nephrol"},{"key":"2812_CR17","doi-asserted-by":"crossref","first-page":"1207","DOI":"10.1016\/S1470-2045(14)70391-2","volume":"15","author":"JF Liu","year":"2014","unstructured":"Liu JF, Barry WT, Birrer M, et al. (2014) Combination cediranib and olaparib versus olaparib alone for women with recurrent platinum-sensitive ovarian cancer: a randomised phase 2 study. Lancet Oncol 15:1207\u20131214","journal-title":"Lancet Oncol"},{"key":"2812_CR18","doi-asserted-by":"crossref","first-page":"429","DOI":"10.1007\/s002800050763","volume":"41","author":"S Piantadosi","year":"1998","unstructured":"Piantadosi S, Fisher JD, Grossman S (1998) Practical implementation of a modified continual reassessment method for dose-finding trials. Cancer Chemother Pharmacol 41:429\u2013436","journal-title":"Cancer Chemother Pharmacol"},{"key":"2812_CR19","doi-asserted-by":"crossref","first-page":"437","DOI":"10.1080\/10543400902800486","volume":"19","author":"A Onar","year":"2009","unstructured":"Onar A, Kocak M, Boyett JM (2009) Continual reassessment method vs. traditional empirically based design: modifications motivated by phase I trials in pediatric oncology by the Pediatric Brain Tumor Consortium. J Biopharm Stat 19:437\u2013455","journal-title":"J Biopharm Stat"},{"key":"2812_CR20","doi-asserted-by":"crossref","unstructured":"Update on the 1987 Task Force Report on High Blood Pressure in Children and Adolescents: a working group report from the National High Blood Pressure Education Program. National High Blood Pressure Education Program Working Group on Hypertension Control in Children and Adolescents (1996) Pediatrics 98 649\u201358","DOI":"10.1542\/peds.98.4.649"},{"key":"2812_CR21","doi-asserted-by":"crossref","first-page":"5296","DOI":"10.1158\/0008-5472.CAN-09-0814","volume":"69","author":"AG Sorensen","year":"2009","unstructured":"Sorensen AG, Batchelor TT, Zhang WT, et al. (2009) A \u201cvascular normalization index\u201d as potential mechanistic biomarker to predict survival after a single dose of cediranib in recurrent glioblastoma patients. Cancer Res 69:5296\u20135300","journal-title":"Cancer Res"},{"key":"2812_CR22","doi-asserted-by":"crossref","first-page":"3069","DOI":"10.1200\/JCO.2009.26.8789","volume":"28","author":"S Gururangan","year":"2010","unstructured":"Gururangan S, Chi SN, Young Poussaint T, et al. (2010) Lack of efficacy of bevacizumab plus irinotecan in children with recurrent malignant glioma and diffuse brainstem glioma: a Pediatric Brain Tumor Consortium study. J Clin Oncol 28:3069\u20133075","journal-title":"J Clin Oncol"},{"key":"2812_CR23","doi-asserted-by":"crossref","unstructured":"Gururangan S, Fangusaro J, Poussaint TY et al. (2013) Efficacy of bevacizumab plus irinotecan in children with recurrent low-grade gliomas\u2014a Pediatric Brain Tumor Consortium study. Neuro Oncol","DOI":"10.1093\/neuonc\/not154"},{"key":"2812_CR24","doi-asserted-by":"crossref","first-page":"1404","DOI":"10.1093\/neuonc\/nos213","volume":"14","author":"S Gururangan","year":"2012","unstructured":"Gururangan S, Fangusaro J, Young Poussaint T, et al. (2012) Lack of efficacy of bevacizumab + irinotecan in cases of pediatric recurrent ependymoma\u2014a Pediatric Brain Tumor Consortium study. Neuro-Oncology 14:1404\u20131412","journal-title":"Neuro-Oncology"},{"key":"2812_CR25","doi-asserted-by":"crossref","first-page":"188","DOI":"10.2967\/jnumed.110.081463","volume":"52","author":"KA Zukotynski","year":"2011","unstructured":"Zukotynski KA, Fahey FH, Kocak M, et al. (2011) Evaluation of 18F-FDG PET and MRI associations in pediatric diffuse intrinsic brain stem glioma: a report from the Pediatric Brain Tumor Consortium. J Nucl Med 52:188\u2013195","journal-title":"J Nucl Med"},{"key":"2812_CR26","doi-asserted-by":"crossref","first-page":"1042","DOI":"10.3174\/ajnr.A1989","volume":"31","author":"AI Holodny","year":"2010","unstructured":"Holodny AI, Makeyev S, Beattie BJ, Riad S, Blasberg RG (2010) Apparent diffusion coefficient of glial neoplasms: correlation with fluorodeoxyglucose-positron-emission tomography and gadolinium-enhanced MR imaging. AJNR Am J Neuroradiol 31:1042\u20131048","journal-title":"AJNR Am J Neuroradiol"},{"key":"2812_CR27","first-page":"17","volume":"53","author":"B Palumbo","year":"2009","unstructured":"Palumbo B, Angotti F, Marano GD (2009) Relationship between PET-FDG and MRI apparent diffusion coefficients in brain tumors. Q J Nucl Med Mol Imaging 53:17\u201322","journal-title":"Q J Nucl Med Mol Imaging"},{"key":"2812_CR28","doi-asserted-by":"crossref","first-page":"1237","DOI":"10.2967\/jnumed.112.115782","volume":"54","author":"KA Zukotynski","year":"2013","unstructured":"Zukotynski KA, Fahey FH, Vajapeyam S, et al. (2013) Exploratory evaluation of MR permeability with 18F-FDG PET mapping in pediatric brain tumors: a report from the Pediatric Brain Tumor Consortium. J Nucl Med 54:1237\u20131243","journal-title":"J Nucl Med"},{"key":"2812_CR29","doi-asserted-by":"crossref","first-page":"573","DOI":"10.1097\/01.mph.0000183863.10792.d4","volume":"27","author":"MW Kieran","year":"2005","unstructured":"Kieran MW, Turner CD, Rubin JB, et al. (2005) A feasibility trial of antiangiogenic (metronomic) chemotherapy in pediatric patients with recurrent or progressive cancer. J Pediatr Hematol Oncol 27:573\u2013581","journal-title":"J Pediatr Hematol Oncol"},{"key":"2812_CR30","doi-asserted-by":"crossref","first-page":"1546","DOI":"10.1111\/j.1349-7006.2012.02333.x","volume":"103","author":"K Matsuki","year":"2012","unstructured":"Matsuki K, Tanabe A, Hongo A, et al. (2012) Anti-angiogenesis effect of 3\u2032-sulfoquinovosyl-1\u2032-monoacylglycerol via upregulation of thrombospondin 1. Cancer Sci 103:1546\u20131552","journal-title":"Cancer Sci"},{"key":"2812_CR31","doi-asserted-by":"crossref","first-page":"12917","DOI":"10.1073\/pnas.2135406100","volume":"100","author":"G Bocci","year":"2003","unstructured":"Bocci G, Francia G, Man S, Lawler J, Kerbel RS (2003) Thrombospondin 1, a mediator of the antiangiogenic effects of low-dose metronomic chemotherapy. Proc Natl Acad Sci U S A 100:12917\u201312922","journal-title":"Proc Natl Acad Sci U S A"},{"key":"2812_CR32","doi-asserted-by":"crossref","first-page":"1570","DOI":"10.1158\/0008-5472.CAN-03-3126","volume":"64","author":"Y Hamano","year":"2004","unstructured":"Hamano Y, Sugimoto H, Soubasakos MA, et al. (2004) Thrombospondin-1 associated with tumor microenvironment contributes to low-dose cyclophosphamide-mediated endothelial cell apoptosis and tumor growth suppression. Cancer Res 64:1570\u20131574","journal-title":"Cancer Res"},{"issue":"4","key":"2812_CR33","doi-asserted-by":"crossref","first-page":"636","DOI":"10.1002\/pbc.24794","volume":"61","author":"NJ Robison","year":"2014","unstructured":"Robison NJ, Campigotto F, Chi SN, Manley PE, Turner CD, Zimmerman MA, Chordas CA, Werger AM, Allen JC, Goldman S, Rubin JB, Isakoff MS, Pan WJ, Khatib ZA, Comito MA, Bendel AE, Pietrantonio JB, Kondrat L, Hubbs SM, Neuberg DS, Kieran MW (2014) A phase II trial of a multi-agent oral antiangiogenic (metronomic) regimen in children with recurrent or progressive cancer. Pediatr Blood Cancer 61(4):636\u2013642. doi: 10.1002\/pbc.24794","journal-title":"Pediatr Blood Cancer"},{"key":"2812_CR34","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1016\/j.cct.2010.03.006","volume":"31","author":"A Onar-Thomas","year":"2010","unstructured":"Onar-Thomas A, Xiong Z (2010) A simulation-based comparison of the traditional method, rolling-6 design and a frequentist version of the continual reassessment method with special attention to trial duration in pediatric phase I oncology trials. Contemp Clin Trials 31:259\u2013270","journal-title":"Contemp Clin Trials"},{"key":"2812_CR35","doi-asserted-by":"crossref","first-page":"2013","DOI":"10.1200\/JCO.2007.14.9930","volume":"26","author":"LB Saltz","year":"2008","unstructured":"Saltz LB, Clarke S, Diaz-Rubio E, et al. (2008) Bevacizumab in combination with oxaliplatin-based chemotherapy as first-line therapy in metastatic colorectal cancer: a randomized phase III study. J Clin Oncol 26:2013\u20132019","journal-title":"J Clin Oncol"}],"container-title":["Child's Nervous System"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00381-015-2812-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00381-015-2812-5\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00381-015-2812-5","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,5,18]],"date-time":"2022-05-18T13:45:02Z","timestamp":1652881502000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00381-015-2812-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,7,19]]},"references-count":35,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2015,9]]}},"alternative-id":["2812"],"URL":"https:\/\/doi.org\/10.1007\/s00381-015-2812-5","relation":{},"ISSN":["0256-7040","1433-0350"],"issn-type":[{"value":"0256-7040","type":"print"},{"value":"1433-0350","type":"electronic"}],"subject":[],"published":{"date-parts":[[2015,7,19]]}}}